nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

02.11.2022 | Letter to the Editor

Positive opinion of the French National Authority for Health on the reimbursement of amyloid tracer (Flutemetamol)

verfasst von: Antoine Garnier-Crussard, Anthime Flaus

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Excerpt

Dear Sir, …

French National Authority for Health - Haute Autorité de santé (HAS). Flutemetamol (VIZAMYL) - Transparency Committee [Internet]. 2022. Available from: https://www.has-sante.fr/upload/docs/evamed/CT-19717_VIZAMYL_PIC_INS_Avisdef_CT19717.pdf. Accessed 25 Aug 2022.

Fantoni ER, Chalkidou A, O’Brien JT, Farrar G, Hammers A. A systematic review and aggregated analysis on the impact of amyloid PET brain imaging on the diagnosis, diagnostic confidence, and management of patients being evaluated for Alzheimer’s Disease. J Alzheimers Dis. 2018;63:783–96.CrossRef

Landau SM, Horng A, Fero A, Jagust WJ. Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI. Neurology. 2016;86:1377–85.CrossRef

French National Authority for Health - Haute Autorité de santé (HAS). Florbetapir (AMYVID) - Transparency Committee [Internet]. 2013. Available from: https://www.has-sante.fr/upload/docs/evamed/CT-12957_AMYVID_PIC_INS_Avis3_CT12957.pdf. Accessed 25 Aug 2022.

French National Authority for Health - Haute Autorité de santé (HAS). Florbetaben (NEURACEQ) - Transparency Committee [Internet]. 2019. Available from: https://www.has-sante.fr/upload/docs/application/pdf/2019-01/neuraceq_pic_ins_avis3_ct16710.pdf. Accessed 25 Aug 2022.

French National Authority for Health - Haute Autorité de santé (HAS) (2017) Flutemetamol (VIZAMYL) - Transparency Committee.

Rabinovici GD, Gatsonis C, Apgar C, Chaudhary K, Gareen I, Hanna L, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019;321:1286.CrossRef

Altomare D, Collij L, Caprioglio C, Scheltens P, van Berckel BNM, Alves IL, et al. Description of a European memory clinic cohort undergoing amyloid-PET: the AMYPAD Diagnostic and Patient Management Study. Alzheimers Dement [Internet]. 2022. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/alz.12696. Accessed 25 Aug 2022.

NCT04426539. New IDEAS: Imaging Dementia-Evidence for Amyloid Scanning Study - A Study to Improve Precision in Amyloid PET Coverage and Patient Care [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT04426539. Accessed 25 Aug 2022.

10.

Cummings J, Lee G, Zhong K, Fonseca J, Taghva K. Alzheimer’s disease drug development pipeline: 2021. Alzheimers Dement (N Y). 2021;7:e12179.

Titel: Positive opinion of the French National Authority for Health on the reimbursement of amyloid tracer (Flutemetamol)
verfasst von: Antoine Garnier-Crussard
Anthime Flaus
Publikationsdatum: 02.11.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 2/2023
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-022-06025-y

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2023

Polar map-free 3D deep learning algorithm to predict obstructive coronary artery disease with myocardial perfusion CZT-SPECT

An EANM position paper on advancing radiobiology for shaping the future of nuclear medicine

Ultra-low dose infection imaging of a newborn without sedation using long axial field-of-view PET/CT

Correction to: European Association of Nuclear Medicine (EANM) response to the proposed ASTRO’s framework for radiopharmaceutical therapy curriculum development for trainees

[18F]-FDG PET and MRI radiomic signatures to predict the risk and the location of tumor recurrence after re-irradiation in head and neck cancer

Adaptive Individualized high-dose preoperAtive (AIDA) chemoradiation in high-risk rectal cancer: a phase II trial